Jacobs Engineering Group Inc (JEC) 51.47 $JEC Jacobs

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Jacobs Engineering Group Inc (JEC) 51.47 $JEC

Jacobs (JEC) Obtains BAYQIK Technology Patent from Bayer
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:05AM CDT
Jacobs Engineering Group Inc. (JEC) recently revealed that it has obtained the patented rights of Bayer AG???s (BAYRY) BAYQIK quasi-isothermal sulfuric acid converter and other associated technology.
BCC: 26.31 (-0.10), JEC: 51.47 (-0.78), WLDN: 18.05 (+0.09)

Jacobs Acquires BAYQIK(R) Sulfuric Acid Converter Technology from Bayer AG
BusinessWire - Wed Aug 31, 6:45AM CDT
Jacobs Engineering Group Inc. (NYSE:JEC) announced today it acquired the patent rights for BAYQIK(R) quasi-isothermal sulfuric acid converter technology and other related technology from Bayer AG.
JEC: 51.47 (-0.78)

NCI Building (NCS) Q3 Earnings: Can the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 8:24AM CDT
NCI Building (NCS) will report its third quarter fiscal 2016 results on Aug 30.
JEC: 51.47 (-0.78), NCS: 14.65 (-0.37), LII: 161.41 (-1.75), LPX: 20.00 (-0.03)

Jacobs (JEC) to Boost Energy Business on TransCanada Deal
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:44AM CDT
Renowned technical services company Jacobs Engineering Group Inc. (JEC) lately inked a three-year deal with the premium North American energy infrastructure company, TransCanada Corporation (TRP).
BCC: 26.31 (-0.10), JEC: 51.47 (-0.78), TRP: 46.98 (+0.29), WLDN: 18.05 (+0.09)

Stock Market News for August 24, 2016
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 8:56AM CDT
Upbeat new-home sales data and better-than-expected European private sector data led the benchmarks to close in the green on Tuesday
JEC: 51.47 (-0.78), MDT: 86.85 (-0.47), MON: 108.02 (+0.58), PFE: 34.88 (+0.11), TREE: 91.78 (-3.91), FCX: 10.62 (+0.14), MRKT: 32.84 (+0.18), MYL: 40.16 (+0.19), BBY: 38.40 (-0.35), LEN: 46.29 (-0.27), AA: 10.17 (+0.04), CF: 25.68 (-0.26), KBH: 15.21 (-0.15), MTH: 35.69 (-0.28), TOL: 30.66 (-0.06), INTU: 110.89 (-1.18)

Jacobs Secures Engineering Services Agreement with TransCanada
BusinessWire - Wed Aug 24, 6:45AM CDT
Jacobs Engineering Group Inc. (NYSE:JEC) announced today it signed a three-year master engineering services agreement with TransCanada Corporation (TSX:TRP) (NYSE:TRP) (TransCanada), a leading energy infrastructure company in North America.
JEC: 51.47 (-0.78), TRP: 46.98 (+0.29), TRP.TO: 60.27 (-0.39)

Jacobs Wins Pfizer's Chinese Bio-Facility Project Contract
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 5:32AM CDT
Jacobs Engineering Group Inc. (JEC) joined hands with Pfizer Inc. (PFE) for developing a new Chinese state-of-the-art biotechnology centre.
JEC: 51.47 (-0.78), PFE: 34.88 (+0.11), AWI: 43.44 (-0.20), WLDN: 18.05 (+0.09)

Jacobs Awarded Design Contract for Pfizer Global Biotechnology Center in China
BusinessWire - Tue Aug 23, 6:45AM CDT
Jacobs Engineering Group Inc. (NYSE:JEC) announced today it was awarded a contract to lead design and provide engineering services, procurement and construction support for Pfizer, Inc.'s new $350 million Global Biotechnology Center investment in the Hangzhou Economic Development Area in China.
JEC: 51.47 (-0.78)

Jacobs Wins Further Contract for Highways England's Roads Investment Program
BusinessWire - Tue Aug 16, 6:45AM CDT
Jacobs Engineering Group Inc (NYSE:JEC) announced today its appointment by Highways England to develop preferred options for multiple highways schemes planned in the east, southeast and northwest regions of England, United Kingdom.
JEC: 51.47 (-0.78)

Downgrade Alert for Jacobs Engineering Group (JEC)
Comtex SmarTrend(R) - Fri Aug 12, 3:16AM CDT
Jacobs Engineering Group (NYSE:JEC) was downgraded from Accumulate to Hold at Johnson Rice today. The stock closed yesterday at $54.41 on volume of 1.2 million shares, above average daily volume of 745,000. Over the past year, Jacobs Engineering Group has traded in a range of $34.76 to $55.89 and closed yesterday at $54.41, 57% above that low. The 200-day and 50-day moving averages have moved 0.24% higher and 1.31% higher over the past week, respectively.
JEC: 51.47 (-0.78)

Jacobs Awarded Contract for Novartis Biotechnology Center Expansion in France
BusinessWire - Thu Aug 11, 6:45AM CDT
Jacobs Engineering Group Inc. (NYSE:JEC) announced today it was awarded a contract to expand the Novartis Pharma S.A.S. Biotechnology Center in Huningue, France.
JEC: 51.47 (-0.78)

AECOM (ACM) Tops Q3 Earnings, Lags Revenues; View Intact
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 8:19AM CDT
AECOM???s (ACM) adjusted earnings per share for third-quarter fiscal 2016 came in at 81 cents, which surpassed the Zacks Consensus Estimate of 71 cents.
JEC: 51.47 (-0.78), ACM: 30.27 (-0.39), WLDN: 18.05 (+0.09), AOS: 96.37 (-0.61)

Jacobs Awarded Transformation Contract with UK Ministry of Defence
BusinessWire - Wed Aug 10, 6:45AM CDT
Jacobs Engineering Group Inc. (NYSE:JEC) announced today it received a contract from the U.K. Ministry of Defence (MOD) to provide technical support to the Service Provision and Transformation Contract associated with the MOD's Strategic Support Supplier Project (SSS) for land equipment use in the United Kingdom.
JEC: 51.47 (-0.78)

SmarTrend Watching for Potential Pullback in Shares of Jacobs Engineering Group After 4.46% Gain
Comtex SmarTrend(R) - Tue Aug 09, 3:09PM CDT
Jacobs Engineering Group (NYSE:JEC) traded in a range yesterday that spanned from a low of $53.53 to a high of $55.89. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $54.38 on volume of 576,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JEC: 51.47 (-0.78)

After Yesterday's Rally of 4.46% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Aug 09, 3:07PM CDT
Jacobs Engineering Group (NYSE:JEC) traded in a range yesterday that spanned from a low of $53.53 to a high of $55.89. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $54.38 on volume of 576,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JEC: 51.47 (-0.78)

Jacobs (JEC) Earnings Top, Revenues Lag Estimates in Q3
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 9:46AM CDT
Jacobs Engineering Group Inc. (JEC) posted adjusted earnings (excluding after-tax costs related to certain restructuring activities) of 78 cents per share in the third quarter of fiscal 2016.
JEC: 51.47 (-0.78), ACM: 30.27 (-0.39), WLDN: 18.05 (+0.09), AOS: 96.37 (-0.61)

Jacobs Engineering Group (JEC) Approaches New Upside Target of $54.77
Comtex SmarTrend(R) - Tue Aug 09, 8:52AM CDT
Jacobs Engineering Group (NYSE:JEC) has opened bullishly above the pivot of $53.69 today and has reached the first level of resistance at $54.08. Should the shares continue to rise, the resistance pivots of $54.77 and $55.85 will be of interest.
JEC: 51.47 (-0.78)

Jacobs (JEC) Beats on Q3 Earnings, Misses Revenues
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 7:25AM CDT
Jacobs Engineering Group Inc. (JEC) reported adjusted earnings per share of 78 cents, up 5.4% with respect to the Zacks Consensus Estimate of 74 cents.
JEC: 51.47 (-0.78)

Jacobs Engineering Group Inc. Reports Earnings for the Third Quarter of Fiscal 2016
BusinessWire - Tue Aug 09, 5:45AM CDT
Jacobs Engineering Group Inc. (NYSE:JEC) today announced its financial results for the third quarter of fiscal 2016 ended July 1, 2016.
JEC: 51.47 (-0.78)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Frontera Energy Set to Release Quarterly Financial Results Soon

Updated Category News Views 253

Frontera Energy Announces First Quarter Financial Results Frontera Energy Corporation (TSX: FEC) has exciting news for its shareholders and interested investors. The Company is set to unveil its financial and operational results for the first quarter, wrapping up on March 31, 2025. This significant announcement will occur after the market closes on a forthcoming Thursday...

Continue Reading
The Rising Value of Contrast Media Injectors in Healthcare

Updated Category News Views 133

Exploring the Global Market for Contrast Media Injectors The global market for contrast media injectors is on the verge of substantial growth, with projections indicating it will reach $2.1 billion in the coming years. This anticipated growth, at a compound annual growth rate (CAGR) of 7.8% from 2025 through 2033, is primarily driven by ongoing advances in technology and...

Continue Reading
Beth Wozniak Sells nVent Electric Shares Worth $884K

Updated Category News Views 158

Beth Wozniak's Recent Stock Sale at nVent Electric Beth Wozniak, Chair & CEO of nVent Electric (NYSE:NVT), executed a significant insider sale recently, as revealed in a new SEC filing. This transaction involved the offloading of 7,597 shares, with a total value of approximately $884,822. Such movements in stock ownership often pique the interest of investors, prompting...

Continue Reading
Electoral Impact of Rising Home Prices on Kamala Harris' Campaign

Updated Category News Views 211

The Impact of Home Prices on the Upcoming Election As we approach the presidential election, the role that home prices play in shaping voter sentiments is becoming increasingly evident. Recent research has shown that fluctuations in the housing market can significantly affect how voters make their choices, particularly in crucial battleground states. Current Trends in...

Continue Reading
Iambic Therapeutics Welcomes Michael Secora as CFO and CDO

Updated Category News Views 134

Iambic Therapeutics Welcomes Michael Secora as CFO and CDO Iambic Therapeutics has announced an important leadership change, appointing Michael Secora, Ph.D., as its Chief Corporate Development Officer and Chief Financial Officer. This decision comes as Iambic continues its commitment to pioneering novel medicines through its innovative AI-driven drug discovery platform....

Continue Reading